COMMUNIQUÉS West-GlobeNewswire

Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
19/12/2024
Company on track to initiate the Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and in other age groups in 2025 NOVATO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. ( [...]
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19/12/2024
SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies [...]
Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options
19/12/2024
Budget impact analysis published in the Expert Review of Ophthalmology journal MENLO PARK, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare [...]
Aptose Announces Positive Decision by Nasdaq Hearings Panel
19/12/2024
SAN DIEGO and TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated [...]
OraSure Technologies Acquires Sherlock Biosciences
19/12/2024
BETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition [...]
CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel
19/12/2024
ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS 19 DECEMBER 2024 at 22.45 EET CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed [...]
U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome
19/12/2024
Company announcement – No. 51 / 2024 U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome The FDA concluded that Zealand [...]
Vittoria Biotherapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of VIPER-101
19/12/2024
Trial is evaluating VIPER-101, a novel, gene edited, autologous dual-population CAR-T therapy in patients with T cell lymphoma VIPER-101 was developed with Vittoria’s proprietary Senza5 platform that features CD5 [...]
Bluejay Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
19/12/2024
REDWOOD CITY, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc., a clinical-stage biopharmaceutical company rapidly progressing transformative therapies for viral hepatitis and other serious liver [...]
Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel
19/12/2024
ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD/MANAGEMENT/AUDITORS 19 DECEMBER 2024 at 19.00 EET Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel [...]
Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
19/12/2024
Jean-Paul Kress to join Sanofi's Board of Directors Paris, December 19, 2024 . Sanofi's Board of Directors is pleased to welcome Jean-Paul Kress as an independent director as of January 1, 2025, replacing Gilles Schnepp [...]
Communiqué de presse - Jean-Paul Kress rejoint le Conseil d’administration de Sanofi
19/12/2024
Jean-Paul Kress rejoint le Conseil d’administration de Sanofi Paris, le 19 décembre 2024 . Le Conseil d’administration de Sanofi est heureux d’accueillir Jean-Paul Kress en qualité d’administrateur indépendant à compter [...]
ONWARD Medical Receives FDA De Novo Classification and US Market Authorization for World’s First Non-Invasive Spinal Cord Stimulation System for People with Chronic Spinal Cord Injury
19/12/2024
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) ARC-EX System is the first and only FDA approved technology shown to improve hand [...]
Smith+Nephew introduces CORIOGRAPH™ Pre-Op Planning and Modeling Services for Total Hip Arthroplasty
19/12/2024
Latest expansion to the CORI ◊ Surgical System portfolio provides a personalized solution for patients and surgeons Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces its CORIOGRAPH [...]
U.S. Oral Surgery Management Secures $175 Million Credit Expansion
19/12/2024
IRVING, Texas, Dec. 19, 2024 (GLOBE NEWSWIRE) -- U.S. Oral Surgery Management (USOSM), the first and largest physician practice management (PPM) company focused exclusively on the oral and maxillofacial surgery [...]
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis
19/12/2024
All four patients treated with NXC-201 normalized their disease markers within 30 days of dosing, of which, two are already classified as complete responders (CR), and the remaining two are bone marrow MRD negative (10 [...]
Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program
19/12/2024
GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving [...]
KFSHRC Inaugurates MENA’s Most Advanced Hematology Diagnostics Laboratory
19/12/2024
RIYADH, Saudia Arabia, Dec. 19, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) inaugurated the Advanced Hematology Diagnostics Laboratory under the patronage of Deputy CEO Dr. [...]
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends
19/12/2024
FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025 Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and [...]

Pages